

SU9516

## Chemical Properties


CAS No. : 377090-84-1

Formula: C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>

Molecular Weight: 241.25

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

Description	SU9516 is a potent CDK2 inhibitor with an IC <sub>50</sub> of 22 nM and also inhibits CDK1 and CDK4, with IC <sub>50</sub> s of 40 nM and 200 nM, respectively.
Targets(IC <sub>50</sub> )	Apoptosis,CDK,Autophagy,p38 MAPK,PKC
In vitro	SU9516 decreases cdk2-specific phosphorylation of the retinoblastoma protein pRB, increases caspase-3 activation, and alters cell cycle in RKO and SW480 cells. SU9516 also inhibits the cell proliferation, and induces cell apoptosis in both cell lines. [1] SU9516 kills leukemic cells through inhibition of RNA Pol II CTD phosphorylation, oxidative damage and transcriptional down-regulation of Mcl-1. [2] In human T-cell leukemia Jurkat cells, SU9516 significantly enhances sensitivity to methotrexate. [3] In addition, SU9516 also suppresses Aurora-A centrosomal localization and consequent centrosome amplification. [4]
Kinase Assay	CDK kinase assay: Kinase assays are performed in 96-well polypropylene plates. Each reaction contained 2 µg of histone H1 at a final concentration of 10 µM [γ-33P]ATP (0.2 µCi/well; approximately twice the experimentally determined K <sub>m</sub> ), 10 mM MgCl <sub>2</sub> , 1 mM DTT, 0.01% Triton X-100, and 10% glycerol in a 40 µL volume. The reaction is initiated with the addition of 20 µL enzyme (6 ng cdk2/well resulting in a final concentration of 1.6 nM), which is previously diluted 1:50-1:200 in the same buffer, and allowed to proceed for 1 h at room temperature. Reaction is stopped by the addition of 0.01 mL 10% phosphoric acid, and 25 µL of reaction mixture is transferred to P30 phosphocellulose filter mat paper. The filter mat is washed three times with 1.0% phosphoric acid, air dried, and then counted for radioactivity in a liquid scintillation counter. The cdk4 kinase assay for cyclin D1-cdk4 is carried out in a polypropylene 96-well microtiter plate format measuring the incorporation of radioactive phosphate into GST-Rb. Purified cyclin D1-cdk4 is incubated with 1 µg GST-Rb in 20 mM HEPES (pH 7.5) in the presence of 10 mM MgCl <sub>2</sub> , 1 mM DTT, 0.01% Triton X-100, and 10% glycerol. The final cdk4 concentration is 10 ng/well, or 1.6 nM. Kinase reaction is initiated by the addition of ATP at a final concentration of 10 µM ATP (twice the experimentally determined K <sub>m</sub> ) and [γ-33P]ATP (1.0 µCi per well) in a 60-µL volume and allowed to proceed at room temperature for 1 h. Reaction is stopped by the addition of 0.01 mL 10% phosphoric acid, and 25 µL of reaction mixture is transferred to P30 phosphocellulose filter mat paper. The filter mat is treated as for Cdk1/Cdk2 assays.

## A DRUG SCREENING EXPERT

Cell Research	Method: Cells are seeded at 2×10 <sup>3</sup> /well of white bottom 96-well plates, treated with INCB018424 from DMSO stocks (0.2% final DMSO concentration), and incubated for 48 hours at 37 °C in an atmosphere containing 5% CO <sub>2</sub> . Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent inhibition relative to vehicle control, and IC <sub>50</sub> curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad.
---------------	---

### Solubility Information

Solubility	DMSO: 55 mg/mL (227.98 mM), Sonication is recommended. Ethanol: 4.8 mg/mL (19.9 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1451 mL	20.7254 mL	41.4508 mL
5 mM	0.829 mL	4.1451 mL	8.2902 mL
10 mM	0.4145 mL	2.0725 mL	4.1451 mL
50 mM	0.0829 mL	0.4145 mL	0.829 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Lane ME, et al. Cancer Res. 2001, 61(16), 6170-6177.

Gao N, et al. Mol Pharmacol. 2006, 70(2), 645-655.

Uchiyama H, et al. Cancer Sci. 2010, 101(3), 728-734.

Leontovich AA, et al. Oncol Rep. 2013, 29(5), 1785-1788.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 36 Washington Street, Wellesley Hills, MA 02481